IDPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomy
Targets (1)
Targets (1)

Get DrugBank to go!

The DrugBank app for iOS and Android is coming soon.

Sign up to get early access
Identification
Name2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline
Accession NumberDB08387
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
MOLSDF3D-SDFPDBSMILESInChI View 3D Structure
SynonymsNot Available
External IDs MP-10
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIIR9Y8EY0G42
CAS numberNot Available
WeightAverage: 392.4525
Monoisotopic: 392.163711282
Chemical FormulaC25H20N4O
InChI KeyAZEXWHKOMMASPA-UHFFFAOYSA-N
InChI
InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3
IUPAC Name
2-{4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxymethyl}quinoline
SMILES
CN1C=C(C(=N1)C1=CC=C(OCC2=NC3=CC=CC=C3C=C2)C=C1)C1=CC=NC=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AProteinunknownNot AvailableHumanQ9Y233 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00149 mg/mLALOGPS
logP5.01ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)4.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.83 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.18 m3·mol-1ChemAxon
Polarizability43.9 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.993
Caco-2 permeable+0.6104
P-glycoprotein substrateNon-substrate0.679
P-glycoprotein inhibitor INon-inhibitor0.5662
P-glycoprotein inhibitor IIInhibitor0.8714
Renal organic cation transporterInhibitor0.6129
CYP450 2C9 substrateNon-substrate0.7196
CYP450 2D6 substrateNon-substrate0.6791
CYP450 3A4 substrateSubstrate0.6687
CYP450 1A2 substrateInhibitor0.8023
CYP450 2C9 inhibitorInhibitor0.6659
CYP450 2D6 inhibitorNon-inhibitor0.7439
CYP450 2C19 inhibitorInhibitor0.7536
CYP450 3A4 inhibitorInhibitor0.6054
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9682
Ames testNon AMES toxic0.6614
CarcinogenicityNon-carcinogens0.9475
BiodegradationNot ready biodegradable0.9877
Rat acute toxicity2.2528 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8211
hERG inhibition (predictor II)Non-inhibitor0.6704
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassAzoles
Direct ParentPhenylpyrazoles
Alternative ParentsQuinolines and derivatives / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
SubstituentsPhenylpyrazole / Quinoline / Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / Pyridine / Heteroaromatic compound / Ether
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Details
1. cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:31 / Updated on June 24, 2017 13:28